Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials.
about
Dapoxetine: a new option in the medical management of premature ejaculationThe office management of ejaculatory disordersEjaculatory dysfunction-the evolution of a new understandingThe drug treatment of premature ejaculationEmerging and investigational drugs for premature ejaculationPatient reported outcomes in the assessment of premature ejaculationThe characterization, current medications, and promising therapeutics targets for premature ejaculationDiscontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation: A 2-Year Prospective Observational StudyAdvances in treating premature ejaculation.An Update of the International Society of Sexual Medicine's Guidelines for the Diagnosis and Treatment of Premature Ejaculation (PE).New insights on premature ejaculation: a review of definition, classification, prevalence and treatmentThe role of dapoxetine hydrochloride on-demand for the treatment of men with premature ejaculationDapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculationPharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers.Medical therapy for premature ejaculation.Evolving therapeutic strategies for premature ejaculation: The search for on-demand treatment - topical versus systemicThe Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy: The PASSION Study.Attitudes of Sexual Medicine Specialists Toward Premature Ejaculation Diagnosis and TherapyTramadol use in premature ejaculation: daily versus sporadic treatmentEfficacy of dapoxetine in the treatment of premature ejaculation.Advances in understanding and treating premature ejaculation.Premature ejaculation: do we have effective therapy?Dapoxetine and the treatment of premature ejaculationEfficacy and safety of dapoxetine in treatment of premature ejaculation: an evidence-based review.Assessing satisfaction in men with premature ejaculation after dapoxetine treatment in real-world practice.A randomized, double-blind, placebo-controlled, crossover trial of "on-demand" tramadol for treatment of premature ejaculation.Impact of physical activity on patient self-reported outcomes of lifelong premature ejaculation patients: Results of a prospective, randomised, sham-controlled trial.Surgery is not indicated for the treatment of premature ejaculation.Contemporary management of ejaculatory dysfunction
P2860
Q24601186-8DEF835C-0823-43A1-A653-8F8B1E6848CFQ28066740-1412760C-3E42-4E77-9F43-8FD2690604FAQ28071637-BB12DB45-9518-49B5-919F-E25A1D861245Q28072609-6A6AC4C7-C7B9-47CB-A955-5A08496831D1Q28078002-FDBAD261-8469-4552-A9AD-446E1F32C15BQ28078604-B970D803-09F6-42AD-9FA8-A6E96B65CC3BQ28081739-83D54B63-540D-4056-95E1-FA7200DC0C1CQ33715864-84DA29A4-9362-4611-B68A-C0CCFBD207D2Q33942072-1D2939EC-D681-49CB-9B3A-5E01994B79CCQ34286787-D7DC79CF-81FF-4B28-9E2C-A25DBBF58ED4Q34306031-13039BAC-5F68-4E5C-BC47-59E5DABE5AB2Q34590149-F6CE6536-990B-4237-AEAE-6DA506558754Q34635746-82685BE9-4D2B-4BB3-B68C-68DD73082B77Q35136178-FFF78B53-ABA3-44A3-8BC3-7F1246A737EBQ35425021-9EF72055-9D31-4E22-A1A0-D57EEDA9A106Q36338826-16C35797-B435-4CCA-9175-5724C9CE7642Q36770029-9A3C3CC9-80B5-4BEC-82F0-EC69A3A29A8BQ37218135-D7841518-F92C-47C8-ACE5-F74051EDEEEEQ37290179-737ED871-C072-463E-BE73-ED2225778729Q37463029-9DAC6F71-3A37-49DA-83E8-7BDEB78EE6B5Q38616683-2C0E0FCC-E361-4FE7-9549-75170A2AF044Q38713715-CB2E2B54-DCFB-4051-B37F-0A16D969E783Q38713732-3009CB2B-996E-44E5-91F8-129630F8F565Q38908136-DCE74CB7-9136-4AF0-9BB8-F285B5983DD2Q40715367-628D9E80-6D75-48C9-B1F4-15B9EEFF5F0FQ42693230-E9FC9054-3C18-40E6-9CDC-10C85E6CEBBBQ48687052-440E3D23-8020-46EE-9A68-DC0574349952Q48791538-AACC6016-A8E3-4698-BC3C-685AC6AE46F5Q58804637-F73A1337-717C-43E5-8382-268F0CB1ADF6
P2860
Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Efficacy and safety of dapoxet ...... ults from five phase 3 trials.
@ast
Efficacy and safety of dapoxet ...... ults from five phase 3 trials.
@en
Efficacy and safety of dapoxet ...... ults from five phase 3 trials.
@nl
type
label
Efficacy and safety of dapoxet ...... ults from five phase 3 trials.
@ast
Efficacy and safety of dapoxet ...... ults from five phase 3 trials.
@en
Efficacy and safety of dapoxet ...... ults from five phase 3 trials.
@nl
prefLabel
Efficacy and safety of dapoxet ...... ults from five phase 3 trials.
@ast
Efficacy and safety of dapoxet ...... ults from five phase 3 trials.
@en
Efficacy and safety of dapoxet ...... ults from five phase 3 trials.
@nl
P2093
P1476
Efficacy and safety of dapoxet ...... ults from five phase 3 trials.
@en
P2093
Chris G McMahon
David A Rivas
Fisseha Tesfaye
Hartmut Porst
Jacques Buvat
Joel M Kaufman
Joseph W Aquilina
Margaret Rothman
Stanley E Althof
Stephen B Levine
P304
P356
10.1111/J.1743-6109.2010.02097.X
P577
2010-11-08T00:00:00Z